MedTrace Logo

Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

NCT00101608 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2010-03-02

No results posted yet for this study

Summary

The purpose of this clinical research study is to learn if vinflunine can shrink or slow the growth of the cancer or increase survival in patients with transitional cell carcinoma of the urothelium. The safety of this treatment will also be studied.

Conditions

  • Transitional Cell Carcinoma
  • Bladder Neoplasms
  • Kidney Neoplasms
  • Ureter Neoplasms
  • Bladder Cancer
  • Neoplasm, Bladder

Interventions

DRUG

vinflunine

solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2007-04-30
Completion
2007-04-30

Countries

  • United States
  • Australia
  • Austria
  • Canada
  • France
  • Greece
  • Indonesia
  • Italy
  • Philippines
  • Singapore
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • Thailand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00101608 on ClinicalTrials.gov